Assessing Ryanodine Receptor Inhibition and Antioxidant Ability of Carvedilol and its Abilities
Abstract
The antioxidant ability of the commonly prescribed antiarrhythmic medication carvedilol was assessed using two distinct assays. The first assay monitored the depletion of the stable radical DPPH via hydrogen atom abstraction utilizing UV-VIS spectrophotometry. The second assay involved monitoring the inhibition of a radical chain reaction initiated by UV light. Three metabolites of carvedilol were synthesized and assessed in each assay along with carvedilol and several benchmark antioxidants to ensure assay validity. It was determined that carvedilol possessed negligible antioxidant ability in both assays, while the metabolites possessed moderate-high antioxidant strength. It is therefore concluded that the antioxidant ability of carvedilol originates from the phenolic metabolites and not from carvedilol itself. The primary function of carvedilol to regulate calcium handling in cardiac myocytes was also assessed for each metabolite using a mutant embryonic cell line. It was determined that metabolic deactivation via hydroxylation pathways is minimal.
Description
Keywords
Chemistry--Organic
Citation
Malig, T. (2016). Assessing Ryanodine Receptor Inhibition and Antioxidant Ability of Carvedilol and its Abilities (Master's thesis, University of Calgary, Calgary, Canada). Retrieved from https://prism.ucalgary.ca. doi:10.11575/PRISM/25020